Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.
about
Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature.Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications.Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patientsPersonalizing health care: feasibility and future implications.Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase.Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French Population-Based Study.Molecular subtyping of brain metastases and implications for therapy.Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases.
P2860
Q30992939-BB6486E3-3E01-4CF0-B575-54FBECA8111AQ31010216-3F0BA0E2-8E27-449F-9F69-0E41B835D3EAQ33842913-6B18BAB6-6559-4B3F-8454-D1FA90C379E4Q34938911-D34CB58D-EE5B-49D0-9EFB-7AD57AEC87B4Q35678734-0340CDD7-CD2A-421A-9E12-F1E79AD72FDEQ39115827-385063DF-CAE6-4AE0-BF28-93B2DA8F28AEQ39373956-7E17C8BB-6E32-4000-AB45-6E8F48082204Q44070495-C742EEBA-A899-4963-B07E-044DC8D564C2Q51497614-46EF9EA0-74BA-473B-B5E4-EE865A5BCA2EQ53118370-C5E811FA-9B27-471C-B244-17C2E3FDED04
P2860
Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Impact of HER-2-targeted thera ...... tive metastatic breast cancer.
@en
Impact of HER-2-targeted thera ...... tive metastatic breast cancer.
@nl
type
label
Impact of HER-2-targeted thera ...... tive metastatic breast cancer.
@en
Impact of HER-2-targeted thera ...... tive metastatic breast cancer.
@nl
prefLabel
Impact of HER-2-targeted thera ...... tive metastatic breast cancer.
@en
Impact of HER-2-targeted thera ...... tive metastatic breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Impact of HER-2-targeted thera ...... itive metastatic breast cancer
@en
P2093
Christoph C Zielinski
Christoph Wiltschke
Guenther G Steger
Margaretha Rudas
Peter Dubsky
Rupert Bartsch
Ursula Pluschnig
Zsuzsanna Bago-Horvath
P2860
P304
P356
10.1111/TBJ.12070
P577
2013-01-27T00:00:00Z